Picture of Themis Medicare logo

THEMISMED — Themis Medicare Share Price

0.000.00%
in flag iconLast trade - 00:00
HealthcareHighly SpeculativeSmall CapHigh Flyer

Momentum

Relative Strength (%)
1m+13.19%
3m
6m
1yr
Volume Change (%)
10d/3m
Price vs... (%)
52w High-22.42%
50d MA
200d MA

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Financial Summary

Year End 31st MarUnit201720182019202020212022E2023ECAGR / Avg
Total RevenueIN₹m2,261.492,117.071,837.552,015.882,306.7n/an/a-0.15%
Operating Profitm
Net Profitm
EPS Reported
Diluted Normalised EPS
EPS Growth%-7.11-30.28n/an/a+44.02n/an/an/a
PE Ratiox
PEG
Profitability
Operating Margin%
ROA%
ROCE%
ROE%
Cashflow
Op. Cashflow ps
Capex ps
Free Cashflow ps
Dividends
Dividend ps
Dividend Growth%
Dividend Yield%
Dividend Coverx
Balance Sheet
Cash etcm
Working Capitalm
NFAm
Net Debtm
Book Valuem
Diluted Weighted Average Sharesm
Book Value ps

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Mar 202231st Mar 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Themis Medicare EPS forecast chart

Profile Summary

Themis Medicare Limited is a pharmaceutical company. The Company is engaged in manufacturing pharmaceuticals and medicinal chemicals. The Company focuses on therapeutic areas, including anti-tuberculosis, anti-malarial, cardiology, pain management, anti-infectives, haematinics, health and nutrition. The Company's active pharmaceutical ingredients (APIs) include Simvastatin, Ethambutol, Artemether, Artesunate, Arteether and Di Methyl Isosorbide. The Company's formulations include original products, new drug delivery systems (NDDS), dietary supplements and others. Its original products include Emal injection, Sepgard Gel, Sepgard Mouth Gargle and Sepgard Solution. The Company's NDDS include Injection Diclofenac Sodium, Gel Diclofenac Diethylamine, Emal Prefilled Injection, Etojet injection and Injection Aceclofenac. The Company offers a range of dietary supplements, which include Gummy Vita (Kids), Gummy Cal (Kids) and Gummy Cal (Adults).

Directors

Last Annual
March 31st, 2021
Last Interim
September 30th, 2021
Incorporated
May 31st, 1969
Public Since
April 2nd, 2007
No. of Shareholders
6,000
No. of Employees
976
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
in flag iconNational Stock Exchange of India
Shares in Issue
9,199,540

THEMISMED Share Price Performance

Similar to THEMISMED

Aarey Drugs and Pharmaceuticals

in flag iconNational Stock Exchange of India

Picture of Aarti Drugs logo

Aarti Drugs

in flag iconNational Stock Exchange of India

Picture of Abbott India logo

Abbott India

in flag iconNational Stock Exchange of India

Picture of Ajanta Pharma logo

Ajanta Pharma

in flag iconNational Stock Exchange of India

Picture of Albert David logo

Albert David

in flag iconNational Stock Exchange of India

FAQ

Or unlock with your email

Or unlock with your email